GEODE CAPITAL MANAGEMENT, LLC - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 196 filers reported holding SAGE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.84 and the average weighting 0.3%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$13,459,798
-39.7%
1,239,097
+4.0%
0.00%
-50.0%
Q1 2024$22,328,652
-11.7%
1,191,331
+2.1%
0.00%
-33.3%
Q4 2023$25,297,297
+11.2%
1,167,257
+5.6%
0.00%0.0%
Q3 2023$22,754,251
-54.7%
1,105,513
+3.6%
0.00%
-50.0%
Q2 2023$50,195,981
+15.0%
1,067,545
+2.6%
0.01%0.0%
Q1 2023$43,648,694
+113500.4%
1,040,245
+3.3%
0.01%
+20.0%
Q4 2022$38,423
-99.9%
1,007,430
+4.5%
0.01%
-16.7%
Q3 2022$37,748,000
+22.5%
963,954
+1.0%
0.01%
+20.0%
Q2 2022$30,826,000
+29.9%
954,373
+33.2%
0.01%
+66.7%
Q1 2022$23,722,000
-38.6%
716,682
-21.1%
0.00%
-40.0%
Q4 2021$38,636,000
-0.3%
908,229
+3.8%
0.01%0.0%
Q3 2021$38,762,000
-11.8%
874,805
+13.1%
0.01%
-16.7%
Q2 2021$43,952,000
-10.7%
773,684
+17.7%
0.01%
-25.0%
Q1 2021$49,211,000
-10.8%
657,464
+3.0%
0.01%
-11.1%
Q4 2020$55,200,000
+50.2%
638,087
+6.1%
0.01%
+28.6%
Q3 2020$36,757,000
+42.5%
601,400
-3.1%
0.01%
+16.7%
Q2 2020$25,796,000
+50.9%
620,400
+4.2%
0.01%
+50.0%
Q1 2020$17,095,000
-79.3%
595,242
-47.9%
0.00%
-55.6%
Q4 2019$82,520,000
+6.3%
1,143,114
+106.5%
0.01%
-50.0%
Q3 2019$77,649,000
-22.4%
553,490
+1.3%
0.02%
-25.0%
Q2 2019$100,053,000
+19.9%
546,472
+4.1%
0.02%
+9.1%
Q1 2019$83,467,000
-6.9%
524,786
-43.9%
0.02%
+57.1%
Q4 2018$89,642,000
+45.6%
935,834
+114.7%
0.01%
-17.6%
Q3 2018$61,568,000
-9.6%
435,884
+0.2%
0.02%
-19.0%
Q2 2018$68,126,000
-1.1%
435,231
+1.7%
0.02%
-4.5%
Q1 2018$68,917,000
+9.9%
427,874
+12.3%
0.02%
+4.8%
Q4 2017$62,737,000
+226.8%
380,896
+23.6%
0.02%
+200.0%
Q3 2017$19,195,000
-17.8%
308,106
+5.1%
0.01%
-22.2%
Q2 2017$23,349,000
+22.7%
293,184
+9.5%
0.01%
+12.5%
Q1 2017$19,036,000
+52.7%
267,861
+9.7%
0.01%
+33.3%
Q4 2016$12,467,000
+19.9%
244,179
+8.2%
0.01%
+20.0%
Q3 2016$10,396,000
+145.3%
225,761
+60.5%
0.01%
+150.0%
Q2 2016$4,238,000
+10.4%
140,674
+17.5%
0.00%0.0%
Q1 2016$3,839,000
-18.3%
119,750
+48.5%
0.00%
-33.3%
Q4 2015$4,701,000
+47.5%
80,650
+7.1%
0.00%
+50.0%
Q3 2015$3,188,000
-40.1%
75,337
+3.4%
0.00%
-33.3%
Q2 2015$5,321,000
+180.8%
72,892
+93.2%
0.00%
+200.0%
Q1 2015$1,895,000
+48.9%
37,728
+8.5%
0.00%0.0%
Q4 2014$1,273,000
+63.6%
34,786
+40.7%
0.00%0.0%
Q3 2014$778,00024,7290.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q2 2017
NameSharesValueWeighting ↓
Third Rock Ventures, LLC 9,773,073$490,901,00052.36%
Ghost Tree Capital, LLC 240,000$12,056,0002.17%
EcoR1 Capital, LLC 112,455$5,649,0001.88%
New Leaf Venture Partners, L.L.C. 43,770$2,199,0001.49%
AlpInvest Partners B.V. 12,195$613,0001.15%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 595,443$29,909,0000.97%
APEX CAPITAL, LLC 190,000$9,544,0000.69%
OAK RIDGE INVESTMENTS LLC 385,770$19,377,0000.43%
Lombard Odier Asset Management (USA) Corp 92,089$4,626,0000.37%
SPHERA FUNDS MANAGEMENT LTD. 65,724$3,301,0000.34%
View complete list of SAGE THERAPEUTICS INC shareholders